Last week we had 10 IPOs, with an average return of 16%. Caesars (NASDAQ:CZR) was a big contributor — it soared 58.20%. But there were six other deals that saw double-digit returns as well:
| company | ticker | return (%) |
| Homestreet | HMST | 0.00 |
| GSE | GSE | 27.80 |
| Synacor | SYNC | 5.00 |
| FX Alliance | FX | 11.10 |
| Caesars | CZR | 58.20 |
| Cementos Pacasmayo | CPAC | -4.30 |
| ChemoCentryx | CCXI | 11.30 |
| EPAM Systems | EPAM | 16.30 |
| Roundys | RNDY | 20.20 |
| Cempra | CEMP | 14.56 |
This week there are only three IPOs planned. Let’s take a look at each:
Ceres (NASDAQ:CERE). The company sells seeds to produce renewable bioenergy feedstocks, which helps reduce reliance on petroleum fuels.
But Ceres’ products are still in the early stages, and sales were only $6.6 million last year, with a net loss of $36.3 million.
The lead underwriter on the deal is Goldman Sachs (NYSE:GS). Ceres plans to issue 5 million shares at a price range of $16 to $17 each, which is down from the prior range of $21 to $23 (indicating soft demand for the transaction).
Brightcove (NASDAQ:BCOV). The company develops a cloud-based platform that allows companies to distribute and manage videos as well as mobile apps.
From 2008 to 2011, revenues jumped from $24.5 million to $63.6 million. But there was a loss of $17.3 million last year.
The company plans to sell 5 million shares at a price range of $10 to $12. The lead underwriter is Morgan Stanley (NYSE:MS).
TVAX Biomedical (NASDAQ:TVAX). This biotech focuses on the development of targeted cell-based treatments for cancer. This involves the use of a cancer cell vaccination and the activation of killer T cells.
After the public offering, the company plans to run a Phase III clinical trial.
TVAX plans to sell 2 million shares at a range of $9 to $11. The lead underwriter is Roth Capital.
Tom Taulli runs the InvestorPlace blog IPO Playbook, a site dedicated to the hottest news and rumors about initial public offerings. He also is the author of “The Complete M&A Handbook”, “All About Short Selling” and “All About Commodities.” Follow him on Twitter at @ttaulli or reach him via email. As of this writing, he did not own a position in any of the aforementioned securities.
A long-time follower of the IPO scene, back in 1999 Tom started one of the first sites in the space called WebIPO. It was a place where investors got research as well as access to deals for the dot-com boom. Tom also wrote the top-selling book, Investing in IPOs. In it, he covers all the aspects of analyzing an IPO, such as reading the prospectus, detecting the risk factors and understanding some of the arcane regulations. But don’t worry — if that process is too intimidating for you, thankfully Tom will do the legwork for you right here in the IPO Playbook blog.
Comments are currently unavailable. Please check back soon.